HK inno.N Corporation
- Biotech or pharma, therapeutic R&D
HK inno.N is a fully integrated pharmaceutical company with a strong R&D and marketing position in South Korea. We have outstanding track-record of new drug commercialization and are actively seeking in-licensing opportunities to expand our pipeline in the areas of chronic diseases (cardiovascular, obesity and endocrine), muscle disorders(cachexia), respiratory diseases(COPD, IPF) and urology.
Our-licensing Assets:
Gastroenterlogy
- Marketed: P-CAB
- P1: i-BAT inhibitor
Dermatology
- P2: Selective JAK1 inhibitor
- PPC: TYK2 inhibitor
Oncology
- Lead: HPK1 inhibitor, EGFR-PROTAC
Others
- JAK1 inhibitor for canine
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}